open access

Vol 6, No 5 (2005): Practical Diabetology
Review articles (submitted)
Published online: 2005-10-03
Get Citation

Visfatin - new adipokine

Magdalena Szopa, Aldona Dembińska-Kieć
Diabetologia Praktyczna 2005;6(5):266-269.

open access

Vol 6, No 5 (2005): Practical Diabetology
Review articles (submitted)
Published online: 2005-10-03

Abstract

Fat tissue produces a variety of secreted proteins (adipocytokines) with important roles in metabolism and inflammation. Visfatin is a newly discovered adipocytokine expressed at high levels in both human and murine visceral fat. Its expression level in plasma increases during the development of obesity. Visfatin was confirmed to be identic to a protein described previously as PBEF (pre-B cell colony-enhancing factor), a 52-kilodalton cytokine expressed in lymphocytes. Visfatin stimulates glucose uptake by adipocyte and muscle cells in vitro and decreases blood glucose levels in mice. Notably, this insulinomimetic factor activates the insulin receptor by binding at a site distinct from that recognizing insulin. Further studies will be required to elucidate a role for visfatin and may lead to interesting insights into new therapies in a variety of inflammatory conditions in metabolic disorders such as diabetes.

Abstract

Fat tissue produces a variety of secreted proteins (adipocytokines) with important roles in metabolism and inflammation. Visfatin is a newly discovered adipocytokine expressed at high levels in both human and murine visceral fat. Its expression level in plasma increases during the development of obesity. Visfatin was confirmed to be identic to a protein described previously as PBEF (pre-B cell colony-enhancing factor), a 52-kilodalton cytokine expressed in lymphocytes. Visfatin stimulates glucose uptake by adipocyte and muscle cells in vitro and decreases blood glucose levels in mice. Notably, this insulinomimetic factor activates the insulin receptor by binding at a site distinct from that recognizing insulin. Further studies will be required to elucidate a role for visfatin and may lead to interesting insights into new therapies in a variety of inflammatory conditions in metabolic disorders such as diabetes.
Get Citation

Keywords

obesity; visceral fat; cytokin; visfatin

About this article
Title

Visfatin - new adipokine

Journal

Clinical Diabetology

Issue

Vol 6, No 5 (2005): Practical Diabetology

Pages

266-269

Published online

2005-10-03

Bibliographic record

Diabetologia Praktyczna 2005;6(5):266-269.

Keywords

obesity
visceral fat
cytokin
visfatin

Authors

Magdalena Szopa
Aldona Dembińska-Kieć

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl